美国肝细胞癌患者生存的种族与民族差异:系统综述与荟萃分析
该系统综述与荟萃分析检索MEDLINE、EMBASE和Cochrane数据库至2020年8月,纳入35项研究共563,097例肝细胞癌患者,评估不同种族和民族在总生存及早期肿瘤检出方面的差异。结果显示,与白人患者相比,黑人患者总生存更差(合并HR 1.08;95%CI 1.05-1.12),西班牙裔(HR 0.92;95%CI 0.87-0.97)和亚裔(HR 0.81;95%CI 0.73-0.88)患者总生存更好;黑人患者早期肝癌检出几率更低(OR 0.66;95%CI 0.54-0.78)。
要点
- 黑人肝细胞癌患者总生存较白人差,西班牙裔和亚裔患者总生存较白人好。
- 黑人患者早期肝癌检出几率显著低于白人患者(OR 0.66;95%CI 0.54-0.78)。
- 亚裔和西班牙裔患者早期肝癌检出几率与白人患者无显著差异。
核心结论
- 美国肝细胞癌预后存在显著种族和民族差异,黑人患者总生存更差,西班牙裔和亚裔患者总生存更好。
- 需要干预措施以减少早期肝癌检出的差异,从而改善肝细胞癌预后。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane数据库从建库至2020年8月。
- 纳入35项报告肝细胞癌种族和民族结局(早期表现和总生存)的研究,共563,097例患者。
- 采用DerSimonian and Laird随机效应模型计算合并风险比(HR)和比值比(OR)。
主要发现
- 纳入患者中53.0%为白人,17.3%为黑人,18.4%为西班牙裔,5.0%为亚裔。
- 与白人患者相比,黑人患者总生存更差(合并HR 1.08;95%CI 1.05-1.12)。
- 与白人患者相比,西班牙裔患者总生存更好(合并HR 0.92;95%CI 0.87-0.97),亚裔患者总生存更好(合并HR 0.81;95%CI 0.73-0.88)。
- 在报告肿瘤分期的20项研究中,黑人患者早期肝细胞癌检出几率低于白人患者(OR 0.66;95%CI 0.54-0.78)。
- 亚裔(OR 1.01;95%CI 0.97-1.05)和西班牙裔(OR 0.87;95%CI 0.74-1.01)患者早期肝细胞癌检出几率与白人患者无差异。
临床怎么用
- 临床应关注肝细胞癌预后的种族和民族差异,尤其黑人患者总生存更差且早期检出几率更低。
- 针对早期肝癌检出差异的干预措施可能有助于改善肝细胞癌预后。
局限性
- 研究最常见局限性为社会经济状况和肝功能不全所致的残余混杂风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States; however, HCC incidence and mortality are not equally distributed among racial and ethnic groups. Our aim was to characterize the direction and magnitude of racial and ethnic disparities in overall survival and early tumor detection among patients with HCC. METHODS: We searched MEDLINE, EMBASE and Cochrane databases from inception through August 2020 for studies reporting HCC outcomes (early stage presentation and overall survival) by race and ethnicity. We calculated pooled hazard ratios (HRs) and odds ratios (ORs) for each racial and ethnic group (White, Black, Hispanic, Asian) using the DerSimonian and Laird method for a random-effects model. RESULTS: We identified 35 articles comprising 563,097 patients (53.0% White, 17.3% Black, 18.4% Hispanic, 5.0% Asian). Compared with White patients, Black patients had worse survival (pooled HR 1.08; 95% CI, 1.05 - 1.12), whereas Hispanic (pooled HR 0.92; 95% CI, 0.87 - 0.97) and Asian (pooled HR 0.81; 95% CI, 0.73 - 0.88) patients had better survival. Among articles reporting tumor stage (n = 20), Black patients had lower odds of early stage HCC compared with White patients (OR, 0.66; 95% CI, 0.54 - 0.78). Conversely, there was no difference in odds of early HCC detection for Asian (OR, 1.01; 95% CI, 0.97 - 1.05) or Hispanic patients (OR, 0.87; 95% CI, 0.74 - 1.01) compared with White patients. The most common limitation of studies was risk of residual confounding from socioeconomic status and liver dysfunction. CONCLUSIONS: There are significant racial and ethnic disparities in HCC prognosis in the United States, with Black patients having worse overall survival and Hispanic and Asian patients having better overall survival compared with White patients. Interventions are needed to reduce disparities in early HCC detection to improve HCC prognosis.
引用
- Rich NE, Carr C, Yopp AC, et al. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020. PMID: 33387668. doi:10.1016/j.cgh.2020.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。